Apotex Sees Low Risk Of Coronavirus Supply Interruption
Canadian Firm Is Country’s Largest API Producer
In addition to securing supply for the short term amid the coronavirus pandemic, Apotex is also “actively preparing for longer term scenarios,” as Canada’s largest pharmaceutical manufacturer and API producer.
You may also be interested in...
India’s Cipla has received the first US approval for a generic rival to Nexium delayed-release oral suspension in the US. The firm recently declared its intention to direct funds to more complex formulations in the US but nevertheless continues to grow its vast portfolio in the market.
California-based Nivagen is continuing to raise money to push through a number of generic launches in the US this year, the company’s founder and chief Jay Shukla told Generics Bulletin.
Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.